Prostate Ca screening interval of 4 years misses few cancers

According to Clarity Pharmaceuticals, the final results are intended to support an application to the FDA for approval of 64Cu-SAR-bisPSMA for imaging in patients with prostate cancer.

In this episode, Janelle Bunce, PA-C, highlights the role that advanced practice providers can play in filling the gaps created by the growing workforce shortages in urology.

"In the 21st century, expert witnesses serve a vital role in presenting evidence to a jury. A good expert will be able to distill complex information into digestible elements the jurors can understand," writes Austin Richards, Esq.

"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.

Taher Naeem, a fourth-year medical student at Baylor College of Medicine, highlights 3 abstracts that were presented during the 24th Annual Fall Scientific Meeting of the SMSNA in San Diego, California.

“Our experience with TULSA demonstrates substantial post-procedure decreases in PSA level, PSA density, and prostate volume,” the researchers wrote.